1
|
Edvardsen H, Brunsvig PF, Solvang H, Tsalenko A, Andersen A, Syvanen AC, Yakhini Z, Børresen-Dale AL, Olsen H, Aamdal S, Kristensen VN. SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance. Pharmacogenomics J 2010; 10:513-23. [PMID: 20157331 DOI: 10.1038/tpj.2010.6] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The dose of docetaxel is currently calculated based on body surface area and does not reflect the pharmacokinetic, metabolic potential or genetic background of the patients. The influence of genetic variation on the clearance of docetaxel was analysed in a two-stage analysis. In step one, 583 single-nucleotide polymorphisms (SNPs) in 203 genes were genotyped on samples from 24 patients with locally advanced non-small cell lung cancer. We found that many of the genes harbour several SNPs associated with clearance of docetaxel. Most notably these were four SNPs in EGF, three SNPs in PRDX4 and XPC, and two SNPs in GSTA4, TGFBR2, TNFAIP2, BCL2, DPYD and EGFR. The multiple SNPs per gene suggested the existence of common haplotypes associated with clearance. These were confirmed with detailed haplotype analysis. On the basis of analysis of variance (ANOVA), quantitative mutual information score (QMIS) and Kruskal-Wallis (KW) analysis SNPs significantly associated with clearance of docetaxel were confirmed for GSTA4, PRDX4, TGFBR2 and XPC and additional putative markers were found in CYP2C8, EPHX1, IGF2, IL1R2, MAPK7, NDUFB4, TGFBR3, TPMT (2 SNPs), (P<0.05 or borderline significant for all three methods, 14 SNPs in total). In step two, these 14 SNPs were genotyped in additional 9 samples and the results combined with the genotyping results from the first step. For 7 of the 14 SNPs, the results are still significant/borderline significant by all three methods: ANOVA, QMIS and KW analysis strengthening our hypothesis that they are associated with the clearance of docetaxel.
Collapse
Affiliation(s)
- H Edvardsen
- Department of Genetics, Institute of Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Helbekkmo N, Sundtroem SH, Aaseboe U, Brunsvig PF, Von Plessen CL, Bremnes RM. A randomized comparison of carboplatin/vinorelbine versus carboplatin/gemcitabine in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7033 Background: Carboplatin/vinorelbine (CV) and carboplatin/gemcitabine (CG) are novel 2-drug combinations in the treatment of NSCLC. In a randomized national multicenter phase III study in stage IIIB and IV patients (pts), we compared these regimens with respect to efficacy, toxicity and quality of life (QoL). Methods: Chemonaive pts with histologically or cytologically proven NSCLC, stage IIIB or IV and ECOG performance status (PS) 0–2 were eligible. There was no upper age limit. Pts received vinorelbine 25 mg/m2 or gemcitabine 1000 mg/m2, both administered on day 1 and 8, in combination with carboplatin (Chatelut AUC 4) at day 1. Three courses were administered in 3-week cycles. QoL questionnaires were completed at baseline, before each cycle and then every 8 weeks up to one year. Primary endpoints were survival and QoL and secondary endpoints toxicity and time to progression (TTP). Stratification was done for age, stage and PS, and the planned sample size per arm was minimum 200. The analyses were performed on an intention-to-treat basis Results: From Oct 2003 through Dec 2004, 433 pts from 33 institutions were randomized to CV (n=218) or CG (n=215). Follow-up was minimum one year. There was no difference in overall survival between the two arms (p=0.89). Median survival was 7.3 vs. 6.5 months and 1-year survival 28% and 31% in the CV and CG arm respectively. TTP was significantly longer in the CG arm (p=0.006) with median TTP 4.2 vs. 3.9 months. There was significantly more grade 3–4 anemia and thrombocytopenia in the CG arm (p<0.001) and more grade 3–4 leucopenia in the CV arm (p= 0.001). More pts in the CG arm needed transfusions of blood (p=0.003) or platelets (p=0.001). There was no difference between the arms with respect to neutropenic infections (p=0.87). QoL data are still being analyzed and will be presented at ASCO. Conclusions: Overall survival was similar in the two treatment arms. In the CG arm, the median TTP was longer, but grade 3–4 toxicity requiring interventions, was more frequent when compared to the VC arm. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. Helbekkmo
- University Hospital of Northern Norway, Tromso, Norway; St. Olavs University Hospital, Trondheim, Norway; Norwegian Radium Hospital, Oslo, Norway; Haukeland University Hospital, Bergen, Norway
| | - S. H. Sundtroem
- University Hospital of Northern Norway, Tromso, Norway; St. Olavs University Hospital, Trondheim, Norway; Norwegian Radium Hospital, Oslo, Norway; Haukeland University Hospital, Bergen, Norway
| | - U. Aaseboe
- University Hospital of Northern Norway, Tromso, Norway; St. Olavs University Hospital, Trondheim, Norway; Norwegian Radium Hospital, Oslo, Norway; Haukeland University Hospital, Bergen, Norway
| | - P. F. Brunsvig
- University Hospital of Northern Norway, Tromso, Norway; St. Olavs University Hospital, Trondheim, Norway; Norwegian Radium Hospital, Oslo, Norway; Haukeland University Hospital, Bergen, Norway
| | - C. L. Von Plessen
- University Hospital of Northern Norway, Tromso, Norway; St. Olavs University Hospital, Trondheim, Norway; Norwegian Radium Hospital, Oslo, Norway; Haukeland University Hospital, Bergen, Norway
| | - R. M. Bremnes
- University Hospital of Northern Norway, Tromso, Norway; St. Olavs University Hospital, Trondheim, Norway; Norwegian Radium Hospital, Oslo, Norway; Haukeland University Hospital, Bergen, Norway
| |
Collapse
|
3
|
Brunsvig PF, Gjertsen MK, Kvalheim G, Aamdal S, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S, Møller M, Eriksen J, Gaudernack G. A phase I/II study of telomerase peptide vaccination of patients with non-small cell lung cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.2580] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. F. Brunsvig
- The Norwegian Radium Hosp, Univ of Oslo, Oslo, Norway; GemVax AS, Oslo, Norway; GemVax AS, Oslo, Norway
| | - M. K. Gjertsen
- The Norwegian Radium Hosp, Univ of Oslo, Oslo, Norway; GemVax AS, Oslo, Norway; GemVax AS, Oslo, Norway
| | - G. Kvalheim
- The Norwegian Radium Hosp, Univ of Oslo, Oslo, Norway; GemVax AS, Oslo, Norway; GemVax AS, Oslo, Norway
| | - S. Aamdal
- The Norwegian Radium Hosp, Univ of Oslo, Oslo, Norway; GemVax AS, Oslo, Norway; GemVax AS, Oslo, Norway
| | - C. J. Markowski-Grimsrud
- The Norwegian Radium Hosp, Univ of Oslo, Oslo, Norway; GemVax AS, Oslo, Norway; GemVax AS, Oslo, Norway
| | - I. Sve
- The Norwegian Radium Hosp, Univ of Oslo, Oslo, Norway; GemVax AS, Oslo, Norway; GemVax AS, Oslo, Norway
| | - M. Dyrhaug
- The Norwegian Radium Hosp, Univ of Oslo, Oslo, Norway; GemVax AS, Oslo, Norway; GemVax AS, Oslo, Norway
| | - S. Trachsel
- The Norwegian Radium Hosp, Univ of Oslo, Oslo, Norway; GemVax AS, Oslo, Norway; GemVax AS, Oslo, Norway
| | - M. Møller
- The Norwegian Radium Hosp, Univ of Oslo, Oslo, Norway; GemVax AS, Oslo, Norway; GemVax AS, Oslo, Norway
| | - J. Eriksen
- The Norwegian Radium Hosp, Univ of Oslo, Oslo, Norway; GemVax AS, Oslo, Norway; GemVax AS, Oslo, Norway
| | - G. Gaudernack
- The Norwegian Radium Hosp, Univ of Oslo, Oslo, Norway; GemVax AS, Oslo, Norway; GemVax AS, Oslo, Norway
| |
Collapse
|
4
|
Borge LM, Brunsvig PF, Ritland S, Stene-Larsen G, Hannisdal E. [The project Better Cancer Care in Buskerud]. Tidsskr Nor Laegeforen 1997; 117:2170-3. [PMID: 9235704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
A project called Better cancer care in Buskerud was started in 1991 in the county of Buskerud, in Norway. The main objective was to improve the out-patient services for cancer patients at the central hospital. In this article we describe the activities at the out-patient clinic during the period 1991-1993. The clinic was staffed by two oncologists and two cancer nurses. A total of 8060 consultations were held with patients during the period. Breast cancer patients comprised the largest group (30%), followed by patients with gastrointestinal cancer (24%) or malignant lymphoma (13%). The hospital's Department of Surgery was particularly relieved to hand over the administration of chemotherapy. The number of patients who received radiotherapy at the nearest cancer centre did not increase, however, during the period. We conclude that the project in Buskerud was a success, and that most of the objectives were achieved.
Collapse
Affiliation(s)
- L M Borge
- Onkologisk poliklinikk Medisinsk avdeling, Buskerud Sentralsykehus, Drammen
| | | | | | | | | |
Collapse
|
5
|
Brunsvig PF, Os I, Frederichsen P. [Hyponatremia. A retrospective study of occurrence, etiology and mortality]. Tidsskr Nor Laegeforen 1990; 110:2367-9. [PMID: 2218994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
In patients admitted to a general medical ward, the incidence of hyponatremia on admission was 3.6%. Mortality was more than three times higher among patients with hyponatremia than among the patients as a whole. The triad hyponatremia, hypoalbuminemia and hypervolemia indicated a poor prognosis. A diversity of medical illnesses was associated with hyponatremia, and the use of diuretics was a major contributor to the electrolyte disturbance. Treatment of asymptomatic hyponatremia is discussed, with special emphasis on restriction of fluids.
Collapse
|
6
|
Brunsvig PF, Reikvam A, Nordgård S. [Protracted digitalis poisoning]. Tidsskr Nor Laegeforen 1987; 107:843-4. [PMID: 3590123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
|